Search

Search results

65 results found

The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence.

Publication: Journal Article

Cheng, K, S Grisendi, J G Clohessy, S Majid, R Bernardi, P Sportoletti, and P P Pandolfi. 2007. “The Leukemia-Associated Cytoplasmic Nucleophosmin Mutant Is an Oncogene With Paradoxical Functions: Arf Inactivation and Induction of Cellular Senescence.”. Oncogene 26 (53): 7391-400.

Services

Page

Providing Expertise in Design and Implementation of Pre-clinical Trials in Mouse Models This facility will work as a resource specializing in preclinical testing in GEMs (genetically engineered mouse models) for investigators with preliminary evidence that an agent or a combination of drugs may...

Vaccine-Educated T cells and a CD123 Bispecific T-Cell Engager for Treatment of Acute Myeloid Leukemia.

Publication: Journal Article

Liegel, Jessica, Dina Stroopinsky, Giulia Cheloni, Dimitra Karagkouni, Myrna Nahas, Yuling Ma, Daniela Torres, et al. 2025. “Vaccine-Educated T Cells and a CD123 Bispecific T-Cell Engager for Treatment of Acute Myeloid Leukemia.”. Blood Advances.

PI3K drives the de novo synthesis of coenzyme A from vitamin B5.

Publication: Journal Article

Dibble, Christian C, Samuel A Barritt, Grace E Perry, Evan C Lien, Renee C Geck, Sarah E DuBois-Coyne, David Bartee, et al. 2022. “PI3K Drives the de Novo Synthesis of Coenzyme A from Vitamin B5.”. Nature 608 (7921): 192-98.

WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.

Publication: Journal Article

Kishikawa, Takahiro, Hiroshi Higuchi, Limei Wang, Nivedita Panch, Valerie Maymi, Sachem Best, Samuel Lee, et al. 2021. “WWP1 Inactivation Enhances Efficacy of PI3K Inhibitors While Suppressing Their Toxicities in Breast Cancer Models.”. The Journal of Clinical Investigation 131 (24).

NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.

Publication: Journal Article

Morel, Katherine L, Anis A Hamid, John G Clohessy, Nicole Pandell, Leigh Ellis, and Christopher J Sweeney. 2021. “NF-κB Blockade With Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.”. Molecular Cancer Research : MCR 19 (7): 1137-45.

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors.

Publication: Journal Article

Chin, Tan-Min, Gandhi T K Boopathy, Ellen P S Man, John G Clohessy, Eva Csizmadia, Margaret P Quinlan, Thomas Putti, et al. 2020. “Targeting Microtubules Sensitizes Drug Resistant Lung Cancer Cells to Lysosomal Pathway Inhibitors.”. Theranostics 10 (6): 2727-43.

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.

Publication: Journal Article

Lee, Yu-Ru, Ming Chen, Jonathan D Lee, Jinfang Zhang, Shu-Yu Lin, Tian-Min Fu, Hao Chen, et al. 2019. “Reactivation of PTEN Tumor Suppressor for Cancer Treatment through Inhibition of a MYC-WWP1 Inhibitory Pathway.”. Science (New York, N.Y.) 364 (6441).

The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care.

Publication: Journal Article

Clohessy, John G, and Pier Paolo Pandolfi. 2018. “The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care.”. Frontiers in Oncology 8: 340.

In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Publication: Journal Article

Chew, Chen Li, Andrea Lunardi, Federico Gulluni, Daniel T Ruan, Ming Chen, Leonardo Salmena, Michiya Nishino, et al. 2015. “In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.”. Cancer Discovery 5 (7): 740-51.